BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
Ella Day | June 6, 2025 | News story | Research and Development | BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types.
BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small cell lung cancer, and a further investigation in triple-negative breast cancer is expected to begin later this year.
The companies will jointly lead a comprehensive development programme, including monotherapy and combination strategies. More than 20 trials are ongoing or planned, with over 1,000 patients treated to date.
“We believe BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumour indications,” said Ugur Sahin, chief executive officer of BioNTech. “Our collaboration with BMS, aims to accelerate BNT327’s development to fully realise its potential.”
Christopher Boerner, chief executive officer of BMS, added: “We are impressed by the innovation that BioNTech has achieved to date, and we look forward to partnering to accelerate existing clinical trials and time to market, while expanding the number of potential indications.”
Ella Day
6/6/25
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …
